Skip to content
XPR – Lifestyle Demo
Author:
Shattuck Labs, Inc.
Shattuck Labs, Inc. Announces Proposed Public Offering
June 9, 2026
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
June 9, 2026
Shattuck Labs Announces Phase 1 Results for SL-325
June 8, 2026
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
June 5, 2026
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 7, 2026